RARE (Ultragenyx Corp) מדד נזילות מהירה
The current quick liquidity position of Ultragenyx Pharmaceutical (RARE) demonstrates the company's solvency, with the latest value recorded as 1.49. The firm adheres to ESG standards by optimizing drug logistics for environmental sustainability. The implementation of AI and robotics in bioanalysis is accelerating drug development. A high-tech R&D pipeline ensures the release of unique mRNA therapies to combat the rarest genetic pathologies.
%20-%20%D7%99%D7%97%D7%A1%20%D7%A0%D7%96%D7%99%D7%9C%D7%95%D7%AA%20%D7%91%D7%99%D7%A0%D7%99%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mvvwvvs9.gq-7b28iyo&start=20220704&end=20261031&filename=GURU_Markets_-_RARE_-_Ultragenyx-Pharmaceutical_-_Intermediate-Liquidity-Ratio "RARE (Ultragenyx Pharmaceutical Inc.) היסטוריית נזילות מהירה מ-04.07.2022 עד 31.10.2026 | 👁️GURU.Markets👁️")
פילוחי מדדים ואנליטיקה של חברת ultragenyx.com (RARE)
The quick ratio measures a company's ability to settle short-term debts using its most liquid assets, intentionally excluding hard-to-sell inventories. By utilizing the quick ratio analysis on GURU.Markets, investors assess the financial cushion of Ultragenyx Pharmaceutical (RARE), which is critical for survival amid costly drug development and fierce competition with biotech behemoths for patent superiority.